ETV7

ETV7 is an ETS-family transcription factor that functions predominantly as a sequence-specific transcriptional repressor, with full repressive activity requiring an isoform containing both its Pointed (PNT) and DNA-binding ETS domains (PMID:11108721). Through direct promoter and chromatin binding it represses a defined set of targets — DNAJC15, where repression drives doxorubicin efflux and chemoresistance (PMID:30025229); the TNFR1-encoding TNFRSF1A gene, where it recruits repressive chromatin remodelers and competes with STAT3 to dampen NF-κB signaling (PMID:37041130); and a signature of interferon-responsive genes, the loss of which promotes cancer stem-like plasticity reversible by IFN-β (PMID:34315857). In other contexts ETV7 acts as a transcriptional activator, driving IFIT3 in colorectal cancer to promote proliferation and migration (PMID:38200280) and upregulating CXCL1 to recruit neutrophils and enhance NET formation, fueling tumor aggressiveness and 5-FU resistance (PMID:41917269). Beyond transcription, ETV7 has a separable cytoplasmic function: it binds the mTOR kinase domain to assemble a rapamycin-resistant complex, mTORC3, that lacks Raptor, Rictor, and mLST8 yet possesses bimodal mTORC1/2 kinase activity and accelerates tumorigenesis (PMID:30258985), with the PNT domain engaging the mTOR FRB sequence and the ETS domain engaging the LBE sequence (PMID:39337528). In CD8+ T cells, ETV7 binds memory and exhaustion gene loci to reshape chromatin accessibility and drive terminal exhaustion, and its depletion improves antitumor T-cell and CAR-T efficacy (PMID:39805956). Across these settings ETV7 behaves as a pro-tumorigenic factor, cooperating with Pten loss to accelerate leukemogenesis (PMID:30478527).

1. 2000 Medium

   Established the foundational molecular identity of ETV7 as a sequence-specific ETS transcriptional repressor and defined the domain requirement for that activity.

   Evidence Reporter and DNA-binding assays with domain-deletion isoforms, repressing RARA and BMP-6

   PMID:11108721

   Open questions at the time

   • Did not identify endogenous physiological targets beyond reporter contexts
   • Repressive cofactors not defined
   • No in vivo or disease context
2. 2013 Medium

   Connected ETV7 transcriptional output to a concrete developmental phenotype, showing it regulates cholesterol synthesis to enable erythropoiesis.

   Evidence Morpholino knockdown in zebrafish with cholesterol rescue and lss expression analysis

   PMID:24357328

   Open questions at the time

   • Ortholog-based, mammalian relevance not tested
   • Direct binding to lss promoter not shown
   • Mechanism linking ETV7 to lss regulation unresolved
3. 2018 High

   Revealed a transcription-independent function: ETV7 nucleates a novel cytoplasmic mTOR complex (mTORC3) that confers rapamycin resistance and drives tumorigenesis.

   Evidence Reciprocal Co-IP, mass spectrometry, rapamycin sensitivity assays, and transgenic rhabdomyosarcoma mouse model

   PMID:30258985

   Open questions at the time

   • Structural basis of complex assembly not resolved
   • Substrate specificity of mTORC3 not fully mapped
   • How ETV7 confers bimodal kinase activity unclear
4. 2018 Medium

   Linked ETV7 repression of DNAJC15 to a clinically relevant chemoresistance mechanism via drug efflux.

   Evidence ChIP/promoter binding, knockdown/overexpression, doxorubicin sensitivity and efflux assays in breast cancer cells

   PMID:30025229

   Open questions at the time

   • Role of DNA methylation as cofactor not mechanistically dissected
   • Repressive chromatin machinery not identified
   • Single lab, single tumor type
5. 2018 Medium

   Demonstrated ETV7 acts as a cooperating oncogene, accelerating leukemogenesis in the context of Pten loss.

   Evidence Transgenic mouse genetic cross with Pten-conditional knockout and colony-forming/self-renewal assays

   PMID:30478527

   Open questions at the time

   • Whether the cooperation is transcriptional or mTORC3-dependent not separated
   • Direct target genes in this context unknown
6. 2021 Medium

   Defined an ETV7-driven immune-evasion axis in which interferon-gene repression promotes cancer stem-like plasticity.

   Evidence Stable overexpression, transcriptome profiling, mammosphere/CD44/CD24 flow cytometry, and IFN-β rescue

   PMID:34315857

   Open questions at the time

   • Direct ETV7 binding at the repressed IFN loci not all confirmed
   • Repressive cofactor identity unclear
7. 2023 Medium

   Provided a mechanistic model for ETV7 repression: chromatin-remodeler recruitment and competition with STAT3 at TNFRSF1A to suppress NF-κB signaling.

   Evidence ChIP, overexpression/knockdown, NF-κB assays, and competitive binding analysis with STAT3 in breast cancer cells

   PMID:37041130

   Open questions at the time

   • Specific chromatin remodelers not named
   • Generality of STAT3 competition across other loci untested
8. 2024 Medium

   Mapped the molecular interface of ETV7-mTOR binding and showed it is therapeutically targetable by competitive displacement.

   Evidence Domain mapping by Co-IP with deletion/mutation constructs and in vivo FRB-domain competitive displacement assay

   PMID:39337528

   Open questions at the time

   • No high-resolution structure of the ETV7-mTOR interface
   • Stoichiometry and other mTORC3 components remain incomplete
9. 2024 Medium

   Extended ETV7 to a transcriptional-activator role, defining an ETV7→IFIT3 axis that promotes colorectal cancer proliferation and migration.

   Evidence Luciferase reporter, RT-qPCR, western blot, siRNA knockdown, and rescue in colorectal cancer cells

   PMID:38200280

   Open questions at the time

   • What determines repressor vs activator behavior of ETV7 not resolved
   • Direct binding at the IFIT3 promoter requires further mapping
10. 2025 High

    Identified ETV7 as a central chromatin node driving CD8+ T-cell terminal exhaustion, with therapeutic implications for T-cell and CAR-T therapy.

    Evidence scRNA-seq, scATAC-seq, gain/loss-of-function in mouse CD8+ T cells, and in vivo solid tumor models

    PMID:39805956

    Open questions at the time

    • Direct vs indirect targets within exhaustion loci not fully separated
    • Cofactors reshaping chromatin accessibility unknown
    • Upstream signals inducing ETV7 in T cells unclear
11. 2026 Medium

    Connected ETV7 transcriptional activation of CXCL1 to a tumor-microenvironment mechanism of neutrophil recruitment, NET formation, and chemoresistance.

    Evidence Overexpression/knockdown, CXCL1 transcription assays, neutrophil/NET assays, and pharmacological inhibition in vitro and in vivo

    PMID:41917269

    Open questions at the time

    • Direct ETV7 occupancy at the CXCL1 promoter not fully established
    • Relationship to other ETV7 axes in colorectal cancer not integrated

• It remains unresolved what molecular switch dictates ETV7's choice between transcriptional repression, transcriptional activation, and cytoplasmic mTORC3 assembly within a given cell.
• No structural model of ETV7 in any complex
• Cofactor partners distinguishing repressor from activator states unidentified
• Crosstalk between mTORC3 activity and ETV7 transcriptional programs untested